Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

Kaleb Yohay, MD, introduces an upcoming Insights series dissecting care for a range of patient ages diagnosed with neurofibromatosis type 1 related plexiform neurofibroma.

A key opinion leader offers a comprehensive overview of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), detailing its symptoms, clinical manifestations, prevalence, and impact on patients' quality of life.

A neurofibromatosis specialist explores the complexities encountered in managing NF1-PN, highlighting the distinct challenges that arise when treating patients across different age groups.

An expert in NF1-PN describes their approach to treatment decision-making for adolescents versus adults, and identifies key barriers and unmet needs in the transition from adolescent to adult care for patients with this condition.

A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.

Kaleb Yohay, MD, an expert in NF1-PN, emphasizes the importance of multidisciplinary and comprehensive team care in managing the condition, detailing the essential team members required to facilitate a successful transition from adolescent to adult care.